Side-by-side comparison of AI visibility scores, market position, and capabilities
Bengaluru India YC W20 creator monetization platform with 4,000+ creators earning $75M+ annually at $5.1M revenue Jun 2024; AI Fiesta with Dhruv Rathee crossed $3M ARR in 36 hours competing with Graphy and Teachable for Indian creator economy.
TagMango is a Bengaluru, India-based creator monetization and digital business platform — backed by Y Combinator (W20) — providing Indian creators, coaches, educators, and subject matter experts with the tools to launch and scale digital businesses through online courses, paid communities, workshops, live sessions, and exclusive content subscriptions. Founded in 2019 by Mohammad Hasan and Divyanshu Damani, TagMango reached $5.1 million in annual revenue in June 2024 and achieved profitability with 4,000+ creators collectively earning over $75 million annually on the platform. In August 2025, TagMango demonstrated its platform scale through the AI Fiesta launch in partnership with popular YouTube creator Dhruv Rathee (25M+ subscribers), which crossed $3 million in annual recurring revenue within 36 hours — establishing TagMango as the platform that can handle viral creator product launches at institutional scale.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.